Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Express Scripts Sees No Commercial Risk From Lupron Subpoena

Executive Summary

Express Scripts does not see any commercial risk from the Boston U.S. Attorney's interest in the patient assistance programs for TAP's Lupron and Prevacid

You may also be interested in...



PBM “Integrity” Will Be Reviewed By CMS In Discount Card Applications

The Centers for Medicare & Medicaid Services will consider the legal actions brought against pharmacy benefit managers and other companies that apply to sponsor a Medicare-endorsed drug discount card

PBM “Integrity” Will Be Reviewed By CMS In Discount Card Applications

The Centers for Medicare & Medicaid Services will consider the legal actions brought against pharmacy benefit managers and other companies that apply to sponsor a Medicare-endorsed drug discount card

FTC Review Of Caremark Deal Will Be Fourth Look At PCS

FTC's review of the Caremark/AdvancePCS merger will be the agency's fourth look at the PCS pharmacy benefit management business in less than a decade - but the first time the agency has considered a straightforward horizontal merger among independent, stand-alone PBMs

Related Content

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel